SEC Form 4 · accession 0001209191-17-038605
Lineage Cell Therapeutics, Inc. · LCTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Russell Skibsted
Officer — Chief Financial Officer
Period of report
Jun 6, 2017
Accepted (ET)
Jun 8, 2017 · 5:18 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000876343
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option to Purchase Common SharesF1 | $3.16 | Jun 6, 2017 | A | 250,000 | A | — | Jun 5, 2027 | Common Shares | 250,000 | 250,000 | D |
Explanation of responses
- F1One quarter of the options shall vest upon the completion of continuous service from the date of grant until February 1, 2018, and the balance of the options shall vest in 36 equal monthly installments, commencing on February 1, 2018, based upon continued service.